What should become a company? Lessons from an academic at the center of biotech translation

About this episode

Klavs Jensen discusses the journey from academic discovery to startup and the factors influencing which scientific breakthroughs become companies.

Guest: Klavs F. Jensen In this episode of Boba & Biotech, I sit down with Klavs Jensen - professor at MIT and former chair of its chemical engineering department - to explore a deceptively simple question: why do some scientific breakthroughs become companies while others never leave the lab? As we unpack the messy journey from academic discovery to startup, Klavs tries his first-ever boba tea, a refreshing mango green tea (sans sugar!) - while sharing candid insights from decades at the intersection of academia, industry, and entrepreneurship. Our conversation dives into the often-misunderstood relationship between universities, startups, and large companies. Klavs explains why many promising ideas are too early for startups, why incremental technologies struggle to displace existing infrastructure, and why timing, talent, and market forces can matter just as much as the science itself. We also explore the human side of innovation: why the skills required to finish a PhD are very different from those needed to build and run a company, and what makes innovation ecosystems like MIT so uniquely effective. Klavs Jensen is the Warren K. Lewis Professor of Chemical Engineering…

People in this episode

Host: Armon Sharei

Guest: Klavs F. Jensen

Topics covered

• biotech
• academic translation
• innovation ecosystems
• entrepreneurship

Keywords

• biotech translation
• startup
• academic discovery
• innovation

Mentioned in this episode

Products: boba tea, mango green tea

Books & works: PhD, MS, Portal

Places: US

More episodes of Boba & Biotech

• Learning Biotech, Surviving Near-Death, and Seeing What Others Don’t · April 23, 2026 · 1h 11m
• Inside the Biotech Incubator: What Early Companies Get Right (and Wrong) · April 9, 2026 · 44 min
• From Lab to Company: Engineering the Next Generation of Biotech Founders · March 13, 2026 · 53 min
• Money Meets Molecules: What Biotech Investors Actually Care About · February 26, 2026 · 43 min
• Building and Scaling the Tools and Technologies that Underpin Lifesciences · February 13, 2026 · 41 min
• Introducing Boba & Biotech: The Only Thing We Sugarcoat is the Boba · January 29, 2026 · 39 min